TY - JOUR
T1 - Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
AU - Helderman, Roxan F. C. P. A.
AU - Loke, Daan R.
AU - Tanis, Pieter J.
AU - Tuynman, Jurriaan B.
AU - Ceelen, Wim
AU - de Hingh, Ignace H.
AU - van der Speeten, Kurt
AU - Franken, Nicolaas A. P.
AU - Oei, Arlene L.
AU - Kok, H. Petra
AU - Crezee, Johannes
N1 - Funding Information:
De manera similar, los estudios VISTA-EMD y VIVID-EMD mostraron la superioridad de aflibercept frente al láser para el tratamiento del EMD, lo que ha permitido su aprobación por la Agencia Europea del Medicamento para esta indicación. Su uso en España para EMD, todavía se encuentra en proceso de negociación de precio/reembolso en el momento de la realiza-ción de esta monografía. Estos datos han sido reforzados por un estudio realizado por el Diabetic Retinopathy Clinical Research Network (DRCR.net) y financiado por el National Institutes of Health (NIH) (Protocolo T), en el que aflibercept mostró una ligera pero significativa mejoría visual en pacien-tes con EMD comparado con bevacizumab y ranibizumab tras un año de seguimiento y con menor número de inyecciones (datos no publicados). En definitiva, contamos con un paso más, que no el último, para el tratamiento de las patologías vasculares de la retina. Su empleo y el estudio de sus resultados nos permitirán opti-mizar el manejo de nuestras consultas y permitirá ampliar el horizonte de nuestros pacientes
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7
Y1 - 2021/7
N2 - Simple Summary Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assists in designing potentially more effective treatment protocols and clinical trials. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In total, 60 articles were included in this study. The selected articles were screened on the HIPEC parameters. Recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
AB - Simple Summary Efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assists in designing potentially more effective treatment protocols and clinical trials. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In total, 60 articles were included in this study. The selected articles were screened on the HIPEC parameters. Recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
KW - peritoneal carcinomatosis
KW - peritoneal metastasis
KW - cytoreductive surgery (CRS)
KW - hyperthermic intraperitoneal chemotherapy (HIPEC)
KW - HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY
KW - COLORECTAL PERITONEAL CARCINOMATOSIS
KW - RECURRENT OVARIAN-CANCER
KW - CYTOREDUCTIVE SURGERY
KW - TISSUE DISTRIBUTION
KW - SYSTEMIC CHEMOTHERAPY
KW - CHEMOPERFUSION HIPEC
KW - COLONIC ANASTOMOSIS
KW - XENOGRAFT MODEL
KW - GASTRIC-CANCER
U2 - 10.3390/cancers13143430
DO - 10.3390/cancers13143430
M3 - (Systematic) Review article
C2 - 34298644
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 14
M1 - 3430
ER -